Premium
Overlap of buspirone with lorazepam, diazepam and bromazepam in patients with generalized anxiety disorder: Findings from a controlled, multicentre, double‐blind study
Author(s) -
Sacchetti Emilio,
Zerbini O.,
Banfi F.,
Tansella M.
Publication year - 1994
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470090604
Subject(s) - bromazepam , buspirone , lorazepam , tolerability , generalized anxiety disorder , diazepam , anxiolytic , psychology , anxiety , alprazolam , anesthesia , panic disorder , double blind , benzodiazepine , anxiety disorder , adverse effect , medicine , psychiatry , placebo , agonist , receptor , alternative medicine , pathology
In a controlled, randomized, multicenter, double‐blind study involving 335 patients with generalized anxiety disorder, buspirone (Busp) was compared to lorazepam, diazepam or bromazepam in order to test its global efficacy, preferential effectiveness in defined subgroups of patients or symptoms, latency of action and safety and tolerability. Apart from minor differences, the dropout rate, the number of subjects for whom the dose was increased, the number of capsules taken daily, the modifications of HRSA, VAS 100 mm, CGIS and CGSRS, the curves of improvement over time, the effectiveness on the somatic and psychic factors of the HRSA, the responsiveness of depressed and non‐depressed anxious patients, and the profiles of adverse events indicated clinical equivalence between the azaspirodecanedione and the comparison benzodiazepines.